Articlenpj aging2026
Stroke in persistent chronic kidney disease condition alters innate-immunity to escalate mitochondrial dysfunction and aging.
Article in npj aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Stroke is one of the leading causes of mortality and disability worldwide, with ischemic stroke accounting for over 87% of all stroke cases. Chronic kidney disease (CKD) is one of the major risk factors for stroke, as CKD patients have shown evidence of impaired cerebral autoregulation leading to exacerbated stroke pathology. The worsening of stroke outcomes in CKD patients is limitedly understood. Inflammation plays a pivotal role in driving the CKD-stroke pathology. The cGAS-STING (cyclic GMP-AMP synthase-stimulator of interferon gene) pathway acts as a key mediator of inflammation in both pathologies. As mitochondrial dysfunction plays a common connecting link between stroke and CKD, activation of the innate-immune response mediated by cGAS-STING pathway becomes inevitable. Therefore, it becomes imperative to understand the role of mitochondria in the exacerbation of stroke outcomes following CKD. In addition, the critical role of altered immune response leading to exacerbated mitochondrial dysfunction and aging in CKD-stroke complex is also crucial to investigate. To study this, CKD was induced in male Sprague Dawley rats followed by middle cerebral artery occlusion (MCAo) to develop a CKD-Stroke complex animal model. Behavioral studies were conducted, and tissues were harvested for biochemical, histological, molecular, mitochondrial and genetic studies. Our findings from transcriptomic and proteomic analyses confirm upregulation of STING, interferons and related genes, alongside downregulation of mitochondrial health markers, in the CKD-stroke complex. This molecular profile reflects accelerated mitochondrial aging due to altered innate immunity mediated by cGAS-STING pathway.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.